1687 related articles for article (PubMed ID: 19445476)
41. Theranostic in Nuclear Medicine - The paradigm of NET.
Giammarile F
Hell J Nucl Med; 2023; 26 Suppl():42-43. PubMed ID: 37658562
[TBL] [Abstract][Full Text] [Related]
42. Preclinical evaluation of the alpha-particle generator nuclide 225Ac for somatostatin receptor radiotherapy of neuroendocrine tumors.
Miederer M; Henriksen G; Alke A; Mossbrugger I; Quintanilla-Martinez L; Senekowitsch-Schmidtke R; Essler M
Clin Cancer Res; 2008 Jun; 14(11):3555-61. PubMed ID: 18519789
[TBL] [Abstract][Full Text] [Related]
43. Application and Dosimetric Requirements for Gallium-68-labeled Somatostatin Analogues in Targeted Radionuclide Therapy for Gastroenteropancreatic Neuroendocrine Tumors.
Taïeb D; Garrigue P; Bardiès M; Abdullah AE; Pacak K
PET Clin; 2015 Oct; 10(4):477-86. PubMed ID: 26384594
[TBL] [Abstract][Full Text] [Related]
44. Structural modifications toward improved lead-203/lead-212 peptide-based image-guided alpha-particle radiopharmaceutical therapies for neuroendocrine tumors.
Lee D; Li M; Liu D; Baumhover NJ; Sagastume EA; Marks BM; Rastogi P; Pigge FC; Menda Y; Johnson FL; Schultz MK
Eur J Nucl Med Mol Imaging; 2024 Mar; 51(4):1147-1162. PubMed ID: 37955792
[TBL] [Abstract][Full Text] [Related]
45. Radiolabeled Somatostatin Analogue Therapy Of Gastroenteropancreatic Cancer.
Bodei L; Kwekkeboom DJ; Kidd M; Modlin IM; Krenning EP
Semin Nucl Med; 2016 May; 46(3):225-38. PubMed ID: 27067503
[TBL] [Abstract][Full Text] [Related]
46. Comparison of the Therapeutic Response to Treatment with a 177Lu-Labeled Somatostatin Receptor Agonist and Antagonist in Preclinical Models.
Dalm SU; Nonnekens J; Doeswijk GN; de Blois E; van Gent DC; Konijnenberg MW; de Jong M
J Nucl Med; 2016 Feb; 57(2):260-5. PubMed ID: 26514177
[TBL] [Abstract][Full Text] [Related]
47. Somatostatin receptor-mediated imaging and therapy: basic science, current knowledge, limitations and future perspectives.
Breeman WA; de Jong M; Kwekkeboom DJ; Valkema R; Bakker WH; Kooij PP; Visser TJ; Krenning EP
Eur J Nucl Med; 2001 Sep; 28(9):1421-9. PubMed ID: 11585303
[TBL] [Abstract][Full Text] [Related]
48. Peptide receptor radionuclide therapy (PRRT) of neuroendocrine tumors with somatostatin analogues.
Bodei L; Pepe G; Paganelli G
Eur Rev Med Pharmacol Sci; 2010 Apr; 14(4):347-51. PubMed ID: 20496546
[TBL] [Abstract][Full Text] [Related]
49. The role of radioactive somatostatin and its analogues in the control of tumor growth.
Krenning EP; Valkema R; Kooij PP; Breeman WA; Bakker WH; de Herder WW; van Eijck CH; Kwekkeboom DJ; de Jong M; Jamar F; Pauwels S
Recent Results Cancer Res; 2000; 153():1-13. PubMed ID: 10626285
[TBL] [Abstract][Full Text] [Related]
50. Evaluation of [99mTc/EDDA/HYNIC0]octreotide derivatives compared with [111In-DOTA0,Tyr3, Thr8]octreotide and [111In-DTPA0]octreotide: does tumor or pancreas uptake correlate with the rate of internalization?
Storch D; Béhé M; Walter MA; Chen J; Powell P; Mikolajczak R; Mäcke HR
J Nucl Med; 2005 Sep; 46(9):1561-9. PubMed ID: 16157541
[TBL] [Abstract][Full Text] [Related]
51. Lutetium-labelled peptides for therapy of neuroendocrine tumours.
Kam BL; Teunissen JJ; Krenning EP; de Herder WW; Khan S; van Vliet EI; Kwekkeboom DJ
Eur J Nucl Med Mol Imaging; 2012 Feb; 39 Suppl 1(Suppl 1):S103-12. PubMed ID: 22388631
[TBL] [Abstract][Full Text] [Related]
52. Tumor response after [(90)Y-DOTA(0),Tyr(3)]octreotide radionuclide therapy in a transplantable rat tumor model is dependent on tumor size.
de Jong M; Breeman WA; Bernard BF; Bakker WH; Visser TJ; Kooij PP; van Gameren A; Krenning EP
J Nucl Med; 2001 Dec; 42(12):1841-6. PubMed ID: 11752083
[TBL] [Abstract][Full Text] [Related]
53. Comparison of 111In-DOTA-Tyr3-octreotide and 111In-DTPA-octreotide in the same patients: biodistribution, kinetics, organ and tumor uptake.
Kwekkeboom DJ; Kooij PP; Bakker WH; Mäcke HR; Krenning EP
J Nucl Med; 1999 May; 40(5):762-7. PubMed ID: 10319747
[TBL] [Abstract][Full Text] [Related]
54. 4D SPECT/CT acquisition for 3D dose calculation and dose planning in (177)Lu-peptide receptor radionuclide therapy: applications for clinical routine.
Kairemo K; Kangasmäki A
Recent Results Cancer Res; 2013; 194():537-50. PubMed ID: 22918781
[TBL] [Abstract][Full Text] [Related]
55. Peptide Receptor Radionuclide Therapy With 177Lu-Octreotate in Patients With Somatostatin Receptor Expressing Neuroendocrine Tumors: Six Years' Assessment.
Hamiditabar M; Ali M; Roys J; Wolin EM; OʼDorisio TM; Ranganathan D; Tworowska I; Strosberg JR; Delpassand ES
Clin Nucl Med; 2017 Jun; 42(6):436-443. PubMed ID: 28263217
[TBL] [Abstract][Full Text] [Related]
56. Theranostics with Ga-68 somatostatin receptor PET/CT: monitoring response to peptide receptor radionuclide therapy.
Kulkarni HR; Baum RP
PET Clin; 2014 Jan; 9(1):91-7. PubMed ID: 25029938
[TBL] [Abstract][Full Text] [Related]
57.
Hicks RJ; Jackson P; Kong G; Ware RE; Hofman MS; Pattison DA; Akhurst TA; Drummond E; Roselt P; Callahan J; Price R; Jeffery CM; Hong E; Noonan W; Herschtal A; Hicks LJ; Hedt A; Harris M; Paterson BM; Donnelly PS
J Nucl Med; 2019 Jun; 60(6):777-785. PubMed ID: 30442752
[TBL] [Abstract][Full Text] [Related]
58. Beta-emitting radionuclides for peptide receptor radionuclide therapy.
Parus JL; Mikolajczak R
Curr Top Med Chem; 2012; 12(23):2686-93. PubMed ID: 23339764
[TBL] [Abstract][Full Text] [Related]
59. Ten years of experience with MIBG applications and the potential of new radiolabeled peptides: a personal overview and concluding remarks.
Shapiro B
Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):150-5. PubMed ID: 9002776
[TBL] [Abstract][Full Text] [Related]
60. Tumor targeting with
Rezazadeh F; Sadeghzadeh N
Chem Biol Drug Des; 2019 Mar; 93(3):205-221. PubMed ID: 30299570
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
